KRAS G12C MUTATION
Clinical trials for KRAS G12C MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C MUTATION trials appear
Sign up with your email to follow new studies for KRAS G12C MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called KQB365 in adults with advanced solid tumors that have KRAS G12S or G12C mutations and haven't responded to standard treatments. The main goals are to find a safe dose and see if KQB365 alone or combined with other drugs can…
Matched conditions: KRAS G12C MUTATION
Phase: PHASE1 • Sponsor: Kumquat Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail shows promise against tough lung cancer before surgery
Disease control Recruiting nowThis study tests a new treatment approach for people with a specific type of lung cancer (KRAS G12C mutation) that can be removed by surgery. About 30 participants will receive a targeted pill (fulzerasib) for 6 weeks, followed by a short break, then 3 cycles of immunotherapy (si…
Matched conditions: KRAS G12C MUTATION
Phase: PHASE2 • Sponsor: Jianxing He • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC